Floatz logo

Lestaurtinib

Childhood T Acute Lymphoblastic Leukemia

Children's Oncology GroupSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Childhood T Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 3BBB
METHOTREXATE
National Cancer Institute (NCI)
Phase 3BBB
PEGASPARGASE
National Cancer Institute (NCI)
Phase 3BBB
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 3BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3BB

View all 37 →

Same molecule, other indications

Lestaurtinib is also rated in:

acute undifferentiated leukemiaDormant
B
Indicative ·
62 / 100
View asset →
myeloid leukemiaDormant
B
Indicative ·
57 / 100
View asset →
acute lymphoblastic leukemiaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →